{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:27:17Z","timestamp":1794482837363,"version":"4.9.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness and safety of short-course MAPK pathway inhibition, integrated with individualized dosimetry, as a redifferentiation strategy in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      This retrospective single-center cohort included 11 patients with RAIR-DTC who underwent genotype-directed redifferentiation therapy with trametinib (\u00b1BRAF inhibition) followed by dosimetry-guided radioiodine therapy. Redifferentiation success was defined on post-redifferentiation diagnostic\n                      <jats:sup>123<\/jats:sup>\n                      I SPECT\/CT as either a \u226530% increase in iodine uptake compared with baseline or any lesion demonstrating activity \u22652 times the mean hepatic uptake. RECIST 1.1 assessments were anchored to the pre-RAI dosimetry time point to isolate the therapeutic contribution of\n                      <jats:sup>131<\/jats:sup>\n                      I Clinical, biochemical, and imaging outcomes, including repeat redifferentiation cycles, were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Restoration of iodine avidity occurred in 10 of 11 patients (91%; exact 95% CI, 0.59\u20131.00). Two patients underwent a second redifferentiation-plus-RAI cycle, both achieving successful reinduction of uptake and durable disease control. Among the 10 patients who received\n                      <jats:sup>131<\/jats:sup>\n                      I, partial response was observed in 8 (80%), stable disease in 1 (10%), and progression in 1 (10%) at 6-month imaging. Serum thyroglobulin trends were generally concordant with structural responses, although interpretation was limited by anti-Tg interference in 3 cases. No grade \u22653 adverse events occurred during redifferentiation or subsequent RAI. Median follow-up was 39 months (IQR: 20\u201354).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Short-course, genotype-directed MAPK inhibition effectively restored iodine avidity and enabled safe, dosimetry-guided radioiodine therapy in a real-world RAIR-DTC cohort. Early structural responses were frequent, toxicity was minimal, and selected patients benefited from repeat redifferentiation cycles. These findings support the use of redifferentiation as a practical bridge to effective RAI and underscore the value of individualized dosimetry in modern RAIR-DTC management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006362","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:00:09Z","timestamp":1771009209000},"page":"e293-e300","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine"],"prefix":"10.1097","volume":"51","author":[{"given":"Mehmet Onur","family":"Demirkol","sequence":"first","affiliation":[{"name":"Departments of Nuclear Medicine and Molecular Imaging, American Hospital \u0130stanbul and Ko\u00e7 University"},{"name":"Department of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, Ko\u00e7 University, \u0130stanbul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3157-5782","authenticated-orcid":false,"given":"Gursan","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Turkish Ministry of Health, Yozgat State Hospital, Yozgat"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulya","family":"Seymen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, Ko\u00e7 University, \u0130stanbul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faruk","family":"Alagol","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, American Hospital \u0130stanbul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Selcukbiricik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine Ko\u00e7 University, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"R1-20260401","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ecl.2018.10.002","article-title":"Evolving understanding of the epidemiology of thyroid cancer","volume":"48","author":"Seib","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"R3-20260401","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3803\/EnM.2019.34.3.215","article-title":"Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy","volume":"34","author":"Liu","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R4-20260401","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1089\/thy.2019.0143","article-title":"Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol","volume":"29","author":"Iravani","year":"2019","journal-title":"Thyroid"},{"key":"R6-20260401","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/thy.2023.0456","article-title":"Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers","volume":"34","author":"Toro-Tobon","year":"2024","journal-title":"Thyroid"},{"key":"R7-20260401","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","article-title":"A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer","volume":"29","author":"Leboulleux","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R8-20260401","first-page":"1124","article-title":"MERAIODE: a phase II redifferentiation trial with trametinib and (131)I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer","volume":"33","author":"Leboulleux","year":"2023","journal-title":"Thyroid"},{"key":"R9-20260401","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/thy.2022.0707","article-title":"Results of the SEL-I-METRY phase II trial on resensitization of advanced iodine refractory differentiated thyroid cancer to radioiodine therapy","volume":"33","author":"Wadsley","year":"2023","journal-title":"Thyroid"},{"key":"R10-20260401","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S2213-8587(25)00064-6","article-title":"Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement","volume":"13","author":"Leboulleux","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"101732","DOI":"10.1016\/j.ando.2025.101732","article-title":"ENDOCAN TUTHYREF network consensus recommendations for refractory thyroid cancer management","volume":"86","author":"Lamartina","year":"2025","journal-title":"Ann Endocrinol (Paris)"},{"key":"R12-20260401","first-page":"1482","article-title":"A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation","volume":"43","author":"Robbins","year":"2002","journal-title":"J Nucl Med"},{"key":"R13-20260401","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","article-title":"Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a single-center prospective two-arm study","volume":"28","author":"Weber","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R14-20260401","first-page":"171","article-title":"The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer","volume":"87","author":"Benua","year":"1962","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"R15-20260401","first-page":"313","article-title":"Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer","volume":"43","author":"Maxon","year":"1999","journal-title":"Q J Nucl Med"},{"key":"R16-20260401","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-06-1753","article-title":"Suppression of BRAF\/MEK\/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant","volume":"13","author":"Liu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R17-20260401","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1172\/JCI89067","article-title":"Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine","volume":"126","author":"Nagarajah","year":"2016","journal-title":"J Clin Invest"},{"key":"R18-20260401","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R19-20260401","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/jc.2018-01478","article-title":"Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20260401","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.3390\/jcm13237021","article-title":"Redifferentiation therapies in thyroid oncology: molecular and clinical aspects","volume":"13","author":"Petranovi\u0107 Ov\u010dari\u010dek","year":"2024","journal-title":"J Clin Med"},{"key":"R21-20260401","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.3390\/ijms20246191","article-title":"Intra- and inter-tumor BRAF heterogeneity in acral melanoma: an immunohistochemical analysis","volume":"20","author":"Ito","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R22-20260401","doi-asserted-by":"crossref","first-page":"840811","DOI":"10.3389\/fimmu.2022.840811","article-title":"Single-cell transcriptome analysis reveals inter-tumor heterogeneity in bilateral papillary thyroid carcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"R23-20260401","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00405-023-07827-y","article-title":"Mutation-based, short-term \u201cneoadjuvant\u201d treatment allows resectability in stage IVB and C anaplastic thyroid cancer","volume":"280","author":"Maurer","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R24-20260401","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"R25-20260401","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.path.2019.08.002","article-title":"Molecular alterations in thyroid carcinoma","volume":"12","author":"Haroon Al Rasheed","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"R26-20260401","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"R27-20260401","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.3390\/ijms23073470","article-title":"State of the art in the current management and future directions of targeted therapy for differentiated thyroid cancer","volume":"23","author":"Silaghi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R28-20260401","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"key":"R29-20260401","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.2021.0565","article-title":"Enhancing radioiodine incorporation in braf-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","journal-title":"Thyroid"},{"key":"R30-20260401","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.3390\/cancers14153800","article-title":"Strategies for radioiodine treatment: what\u2019s new","volume":"14","author":"Sparano","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:00:55Z","timestamp":1775077255000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006362","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"2025-11-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}